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SCHOLZ,HOLGER,ANDARMINKURTZ. Roleofproteinkinase 
C in renal vasoconstriction caused by angiotensin II. Am. J. 
Physiol. 259 (Cell Physiol. 28): C421C426, 1990.-In this 
study we have examined the subcellar pathways along which 
angiotensin II (ANG II) causes renal vasoconstriction. Using 
the isolated perfused rat kidney model, we found that renal 
vasoconstriction produced by ANG II (100 PM) was not altered 
by the calmodulin antagonists calmidazolium (1 PM) and N- 
(6-aminohexyl)-5-chloro-1-naphthalensulfonamide (W-7, 10 
PM) but was blunted by staurosporine (100 nM) and 1-(5- 
isoquinolinylsulfonyl)-2-methyl-piperazine (H-7, 50 PM), two 
structurally distinct putative protein kinase C inhibitors. The 
phorbol ester 4cy-phorbol12,13-didecanoate (l-100 nM) did not 
alter renal vascular resistance, whereas phorbol 12-myristate 
13-acetate (PMA, l-100 nM) caused potent and dose-depend- 
ent vasoconstriction that was prevented by staurosporine (100 
nM) and H-7 (50 PM). The vasoconstrictory effects of ANG II 
and PMA were attenuated by the calcium channel blockers 
verapamil (5 PM) and nifedipine (5 PM) and were reversibly 
inhibited when cobaltous chloride (2 mM) was added to the 
perfusate. Taken together, our findings support the concept 
that the renal vasoconstrictory effect of ANG II is essentially 
mediated by protein kinase C activation, which either requires 
or enhances the entrance of extracellular calcium. 
angiotensin II; kidney; calcium; calmodulin; calcium channels 
ANGIOTENSIN II (ANG II) is known as a potent renal 
vasoconstrictor that acts on all parts of the arterial tree 
in the kidney (4). The subcellular pathways, however, 
along which ANG II exerts its effect on smooth muscle 
cells in the kidney are less understood. Some evidence 
suggests that the renal action of ANG II might have 
some special characteristics. For instance, it was shown 
recently that the constrictor effect of ANG II is blunted 
by organic calcium channel blockers in the preglomerular 
arteriole but not affected in the efferent arteriole (7,12). 
This phenomenon raises the question about the media- 
tion of the effect of ANG II on a cellular level. 
In cultures of vascular smooth muscle cells, ANG II 
has been found to stimulate phospholipase C activity, 
thus producing inositol trisphosphate and diacylglycerol 
(2), which lead to calcium mobilization and activation of 
protein kinase C, respectively (3, 8). Moreover, ANG II 
enhances transmembrane calcium influx in its target 
cells (2, 22, 23, 38). Whether this effect is mediated by 
receptor-operated second messenger-activated or by volt- 
age-gated calcium channels is still a matter of debate. 
Calcium mobilization brought about by release from 
intracellular stores and by enhancement of transmem- 
brane influx is thought to initiate smooth muscle cell 
contraction by activating myosin light chain kinase, an 
effect that is mediated by a calcium-calmodulin-depend- 
ent reaction (19, 32, 33). In fact, a number of studies 
have provided evidence that the constrictor effect of 
ANG II is attenuated by organic and inorganic calcium 
channel blockers, suggesting an important role of trans- 
membrane calcium entry in the action of ANG II (11, 
20, 26, 29). 
The physiological role of protein kinase C activation 
in smooth muscle cell contraction is less understood. It 
has been found that activators of protein kinase C cause 
a calcium-dependent delayed contraction of several 
smooth muscle cell types (1, 32-34). A present concept 
is that protein kinase C activation is necessary for the 
sustained contraction induced by vasoconstrictor hor- 
mones (1, 32-34). Most of the findings, however, were 
obtained with preparations of isolated smooth muscle 
cells, and it was our interest therefore to test the impor- 
tance of the beforementioned subcellular pathways for 
the behavior of vascular smooth cells in the intact kidney 
in response to ANG II. 
Using the isolated rat kidney perfused at constant 
pressure as a model, we have therefore examined the 
effects of calmodulin, protein kinase C, and calcium 
channel inhibitors on the renal vasoconstriction induced 
by ANG II. 
MATERIALS AND METHODS 
Male SIV strain rats (250-350 g body wt) with free 
access to tap water and commercial pellet chow until the 
day of experiment were used throughout. According to 
the technique described by Schurek and Alt (36), isolated 
kidney perfusion was performed as follows: anesthesia of 
the animals was obtained by intraperitoneal injection of 
150 mg/kg of 5-ethyl-5-( l-methylpropyl)-2-thio-barbi- 
turic acid (Inactin, Byk Gulden, Constance, FRG). The 
preparation was performed during artificial respiration 
with 25% O2 maintained by a Harvard respirator (75 
strokes/min, stroke volume 2 ml). The animals were 
substituted for volume loss by intermittent injections of 
small volumes (-0.5 ml each) of physiological saline into 
a catheter inserted in the jugular vein. After abdominal 
midline incision, the right kidney was exposed and placed 
in a thermostated metal chamber that was fixed at a 
micropuncture table. After intravenous heparin injection 
(2 U/g body wt, Liquemin, Roche, Basel, Switzerland), 
the arterial vessels branching off the abdominal aorta 
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were ligated. A double-barreled cannula was inserted in 
the aorta and placed directly at the origin of the right 
renal artery. Renal ischemia was avoided by starting the 
perfusion in situ with an initial perfusion flow rate of 8 
ml/min. Thereafter, the kidney was isolated from the 
animal, and -10 min later, constant perfusion pressure 
of 100 mmHg was established. Perfusion pressure was 
monitored through the inner part of the cannula (Sta- 
tham transducer PlO EZ) and kept constant by means 
of a feedback-regulated peristaltic pump. The basic per- 
fusion medium (ZOO-220 ml) consisted of a Krebs-Hen- 
seleit solution containing all physiological amino acids 
in concentrations between 0.2 and 2.0 mM, as well as (in 
mM) 8.7 glucose, 0.3 pyruvate, 2.0 L-lactate, 1.0 cu-keto- 
glutarate, 1.0 L-malate, and 6.0 urea. Thyroid hormone 
(T3, 150 ng/lOO ml), vasopressin 8-lysine (1 mU/lOO ml), 
and 2 g/100 ml of bovine serum albumin were also added 
to the perfusate. Ampicillin (3 mg/lOO ml) and fluclox- 
acillin (3 mg/lOO ml) were used as antibiotics. Hemato- 
crit was adjusted to 10 t 2% by the addition of three 
times freshly washed human erythrocytes. During the 
preperfusion period, before the erythrocytes were added, 
an in-line filter (&pm pore size) was used to remove 
small particles from the perfusate. The perfusate medium 
was continuously dialyzed against a 200fold volume of 
protein-free saline. Adequate oxygen supply to the kid- 
ney was maintained by equilibrating the dialysate with a 
gas mixture containing 95% oxygen-5% carbon dioxide. 
Perfusion flow rate was obtained from the revolutions of 
the peristaltic pump, which was calibrated before and 
after each experiment. Flow rate and perfusion pressure 
were monitored by a potentiometric recorder (Kipp & 
Zonen, Delft, The Netherlands). Stock solutions of the 
tested drugs (see below) were dissolved in freshly pre- 
pared perfusion medium and directly infused into the 
arterial limb of the perfusion circuit via a micromagnetic 
stirrer chamber. Flow proportional infusion rate of 2% 
of perfusion flow was performed by means of a peristaltic 
pump (2132 Microperpex, LKB, Bromma, Sweden). 
Agents. Pyruvate was from Boehringer, Mannheim, 
FRG. Ampicillin and flucloxacillin came from Beecham, 
Bern, Switzerland. Glutamate, urea, and a-ketoglutarate 
were obtained from Merck, Darmstadt, FRG. L-Malic 
acid and L-lactate as sodium salts were provided by 
Serva, Heidelberg, FRG. Thyroid hormone was from 
Henning, Berlin, and L-amino acids were from Braun/ 
Melsungen, FRG (Aminoplasmal free of carbon hydrate). 
Vasopressin 8-lysine was supplied by Sandoz, Basel, 
Switzerland. Bovine serum albumin, ANG II, phorbol 
12-myristate 13-acetate (PMA), 4a-phorbol l&13-dide- 
canoate (PDD), nifedipine, JV- (6-aminohexyl) -&chloro- 
l-naphthalensulfonamide (W-7), and 1-(5-isoquinolinyl- 
sulfonyl)-2-methyl-piperazine (H-7) were purchased 
from Sigma International. Calmidazolium and stauros- 
porine were from Calbiochem. Verapamil was obtained 
from Knoll, Ludwigshafen, FRG. 
Presentation of results. Graphs shown are precise re- 
drawings from original traces. To indicate that redraw- 
ings were made, the data points from the original traces 
are also shown in Figs. 1-9. Numbers (n) in brackets 
given in RESULTS indicate the number of different kid- 
neys with which a certain experiment was performed. 
RESULTS 
Basal flow rate through the isolated perfused rat kid- 
ney (IPRK) under our experimental conditions was 11.8 
t 1.9 (SE) mlmin-leg kidney-’ (n = 10). 
ANG II (100 PM) elicited a prompt, reversible, and 
reproducible reduction of perfusate flow rate in the IPRK 
perfused at 100 mmHg (Fig. 1). The delay of action of 
ANG II in our system was ~20 s (15 t 2 s, n = 10). 
Initially, ANG II reduced flow rate by 9 t 2 ml. rninm2. g 
kidney-’ (n = 10). After 5 min on average, flow rate was 
decreased to 40 t 5% of the control value in presence of 
ANG II (100 pM, n = 10). Addition of calmidazolium (1 
PM), a calmodulin antagonist (14), to the perfusate had 
no effect on basal flow rate (Fig. 2). The constrictory 
effect of ANG II was also unaltered by calmidazolium 
(Fig. 2, n = 4). W-7 (10 PM), another putative calmodulin 
antagonist (17), did not affect the response to ANG II 
(data not shown, n = 3). The protein kinase C inhibitor 
staurosporine (100 nM, Ref. 39) caused a slowly devel- 
oping increase of renal flow rate that was dependent on 
the concentration used (Fig. 3, n = 3). At a concentration 
of 30 nM, staurosporine increased basal perfusion flow 
by 5 t 1% (n = 3). Staurosporine applied at 100 nM led 
to an increase of basal renal flow rate by 13 t 3% of 
control (n = 3). Moreover, staurosporine, inhibited the 
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FIG. 1. Effect of angiotensin II (ANG II) on perfusate flow rate of 
isolated rat kidneys perfused at constant pressure (100 mmHg). Basal 
perfusion flow was 11.8 k 1.9 mlmin-‘*g kidney-’ &SE, n = 10). ANG 
II (100 pM) reversibly reduced renal perfusion flow rate to 40 t 5% of 
control (n = 10). Note that no desensitization of vasoconstrictory effect 
occurred when ANG II (100 PM) was applied repeatedly at 25-min 
intervals. 
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FIG. 2. Effect of calmidazolium (CMDZ) on renal flow rate and 
constrictory response to ANG II (100 PM). CMDZ (1 PM) affected 
neither basal flow rate nor vasoconstrictor effect of ANG II (n = 4). 
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FIG. 3. Effect of staurosporine (stauro A) on basal perfusate flow 
rate and ANG II-induced renal vasoconstriction. Stauro A (30 and 100 
nM) caused a slowly developing increase of renal flow rate of 5 t 1 and 
13 t 3% of control, respectively (n = 3 each). Furthermore, a dose- 
dependent inhibition of the constrictory effect of ANG II (100 PM) was 
observed with a half-maximal effective dose estimated to be -50 nM. 
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FIG. 4. Effect of 1-(5-isoquinolinylsulfonyl)-2-methyl-piperazine 
(H-7) on basal renal flow rate and constrictory response to ANG II 
and KCl. H-7 (30 PM) reversibly increased basal perfusion flow by 19 
t 3% of control (n = 3) and markedly attenuated ANG II-induced (100 
PM) renal vasoconstriction (n = 3). In contrast, constrictor effect of 
KC1 (30 mM) was only slightly affected by H-7 applied at concentra- 
tions of lo-50 PM (n = 3). 
constrictory effect of ANG II in a dose-dependent fashion 
(Fig. 3). From three log (flow rate)-log (concentration) 
relationships, the concentration of staurosporine re- 
quired to inhibit the effect of ANG II half maximally 
was estimated to be -50 nM. 
H-7, another putative protein kinase C inhibitor that 
structurally differs from staurosporine (16)) also caused 
a dose-dependent and reversible increase of basal perfus- 
ate flow rate by 19 t 3% of control when applied at a 
concentration of 30 PM (Fig. 4, n = 3). H-7, moreover, 
inhibited the constrictory response to ANG II (100 PM) 
in a concentration-dependent fashion with a half-maxi- 
mal effective dose (ED& value estimated to be -30 FM 
(Fig. 4). 
Like with ANG II, the administration of KC1 led to a 
prompt reduction of renal perfusion flow rate that was 
dose dependent and fully reversible. At a concentration 
of 30 mM, KC1 decreased basal flow rate to 8 & 1% of 
control (Fig. 4, n = 5). In contrast to ANG II, KCl- 
induced deceleration of flow rate was only slightly de- 
creased after a lo-min preincubation with H-7 applied 
at concentrations of lo-50 PM (Fig. 4). 
PMA, an activator of protein kinase C (28), caused a 
protracted, strong, and persisting reduction of flow rate. 
The deceleration of flow rate induced by PMA was 
concentration dependent (Fig. 5). PMA applied at con- 
centrations of 10 and 100 nM decelerated flow rates by 
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FIG. 5. Dose-dependent decrease of renal perfusate flow in response 
to phorbol 12-myristate 13-acetate (PMA). PMA (10 and 100 nM)- 
induced deceleration of flow rates was 0.5 * 0.2 and 1.5 k 0.1 ml. 
minm2 l g kidney-‘, respectively (n = 3). PMA, at a concentration of 100 
nM, reduced flow rates to 15 t 5% of control values (n = 3). Note that 
strong vasoconstrictory effect persisted after termination of PMA 
application. 
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FIG. 6. Effect of cobaltous chloride, verapamil (VP), nifedipine 
(NP), and staurosporine (staurosporin A) on PMA-induced renal vaso- 
constriction. Cobalt (2 mM, n = 4), as well as calcium channel blockers 
VP (5 PM, n = 4) and NP (5 PM, n = 4), reversibly attenuated reduction 
of flow rate elicited by PMA (100 nM). In comparison, staurosporin A 
(100 nM) caused a more slowly developing and protracted reduction of 
vasoconstrictory effect of PMA (n = 3). 
0.5 t 0.2 (n = 3) and 1.5 t 0.1 ml l rninm2. g kidney-‘, 
respectively (Fig. 5, n = 5). At a concentration of 100 
nM, PMA decreased flow rates to 15 t 5% of the control 
value (n = 5). With respect to the deceleration of flow 
rates, the concentration of PMA required to achieve half- 
maximal effect was estimated to 30 nM. Flow reduction 
by PMA (100 nM) was inhibited by a lO-min preincu- 
bation with staurosporine (100 nM, n = 4) and H-7 (50 
PM, n = 3), respectively (data not shown). At a concen- 
tration of 100 nM, PMA caused a long-lasting reduction 
of blood flow that was partly reversed by staurosporine 
(Fig. 6). PDD, a phorbol ester inactive protein in protein 
kinase C stimulation (28), had no effect on the flow rate 
when applied in a concentration range from 1 to 100 nM 
(data not shown, n = 3). 
Addition of cobaltous chloride (2 mM) to the perfusate 
significantly increased basal flow rate by 22 t 2% (n = 
4). Cobalt prevented the reduction of flow rate by ANG 
II (100 pM, n = 4), an effect that was fully reversible 
immediately after removal of cobalt (Fig. 7). Cobaltous 
chloride also blunted the effect of PMA (100 nM, n = 3, 
Fig. 8). Verapamil (5 PM) and nifedipine (5 PM) in- 
creased basal flow rates by 18 & 6 and 21 t 5%, respec- 
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FIG. 7. Effect of cobaltous chloride on renal perfusate flow and 
ANG II-induced vasoconstriction. Cobalt (2 mM) caused a slight but 
significant increase of basal flow rate by 22 & 2% of control (n = 4) 
and reversibly reduced vasoconstrictory effect of ANG II (100 nM, n = 
4). 
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FIG. 8. Effect of cobaltous chloride on basal perfusate flow rate and 
PMA-induced renal vasoconstriction. Cobalt (2 mM) significantly in- 
creased basal perfusion flow rate and blunted constrictory response to 
PMA (100 nM, n = 3). Note that after removal of cobalt PMA elicited 
prompt and sustained vasoconstriction. As control, constrictory effect 
of ANG II (100 PM) is shown. 
G 20r 
.- F 16- 
5 
al 12 - 
z 
g  a- = 
5 
.- rn 4- 
3 w- 
G 
a O- 
ANG II c( ANG 11 NifedGe k I 
b 4 
10 min 
FIG. 9. Effect of calcium entry blockers verapamil and nifedipine 
on renal flow rate and ANG II-induced renal vasoconstriction. Verap- 
amil (5 PM) and nifedipine (5 PM) significantly increased basal flow 
rates by 18 t 6 and 21 t 5%, respectively (n = 3 each), and reversibly 
attenuated reduction of perfusate flow caused by ANG II (100 PM). 
tively (n = 4 for each drug). Both drugs attenuated the 
reduction of flow rate caused by ANG II (Fig. 9). In the 
presence of verapamil(5 PM) or nifedipine (5 PM), ANG 
II (100 PM) decreased renal perfusate flow only to 86 t 
3% of control (n = 3 each) as compared with 40 t 5% 
when ANG II (100 pM) was applied alone (see above). 
Like cobaltous chloride, verapamil and nifedipine revers- 
ibly attenuated also the drop of flow rate induced by 
PMAby -50% (47 t 3%, Fig.6, n = 3). 
DISCUSSION 
Our findings show and thus extend previous findings 
that ANG II is a potent vasoconstrictor in the rat kidney 
(4). Doubtless ANG II exerts a direct effect on vascular 
smooth muscle cells in the kidney (12). Recent experi- 
mental evidence, moreover, shows that ANG II also 
affects the sodium transport in the proximal tubule (25). 
As a consequence, ANG II may influence the tubuloglo- 
merular feedback (TGF) by its tubular effect, thus acting 
indirectly on renal vascular resistance. Therefore the 
direct action of ANG II on renal vascular smooth muscle 
cells may be superimposed by its tubular effect. In our 
experimental system, we have no evidence for a function- 
ing TGF. For instance, average sodium reabsorption is 
<9O% of the filtered load (35). If present, TGF responses 
should be maximally activated under these conditions, 
because the sodium chloride load at the macula densa is 
expected to be strongly increased. Therefore, we suppose 
that the effects of ANG II as seen in this study are 
predominantly due to direct actions of ANG II on vas- 
cular smooth muscle cells in the kidney. 
The calmodulin antagonists W-7 and the more specific 
calmidazolium were without any effect on ANG II-in- 
duced renal vasoconstriction. At the same concentra- 
tions, both drugs blunted erythropoietin formation in 
response to hypoxia in the same kidney model (35). Thus 
the concentrations of the calmodulin antagonists used 
were sufficient to exert cellular effects, and, in conse- 
quence, our findings suggest that either the calmodulin 
species in renal vascular smooth muscle is not susceptible 
to calmidazolium and W-7 or that a calmodulin-mediated 
reaction is not the dominant subcellular pathway for 
renal vasoconstriction induced by ANG II. On the other 
hand, staurosporine, a putative protein kinase C inhibi- 
tor, blunted the constrictory response to ANG II with an 
ED50 of -50 nM. This value argues in favor that the 
effect of staurosporine was mediated by protein kinase 
C inhibition rather than by inhibition of other enzymes. 
Moreover, H-7, a structurally different putative inhibitor 
of protein kinase C also inhibited ANG II-induced renal 
vasoconstriction in a dose-dependent fashion with an 
estimated EDso of -30 PM. The specificity of the effect 
of H-7 was supported by the finding that the constrictory 
response to KC1 was only slightly affected by H-7 applied 
in a concentration range of lo-50 PM, whereas ANG II- 
induced vasoconstriction was markedly attenuated. Con- 
versely, direct stimulation of protein kinase C by active 
phorbol esters such as PMA caused a dose-dependent 
constriction, whereas phorbol esters that do not activate 
protein kinase C such as PDD had no effect on renal 
vascular resistance. A constrictory effect of phorbol es- 
ters has also been observed in other smooth muscle cell 
preparations (6,30). Unlike with these findings, however, 
the constrictory effect of PMA in the kidney occurred 
with only a brief period of delay (Cl min), which could 
reflect a realistic time requirement for the activation of 
protein kinase C by phorbol esters (28). 
Because it is known that ANG II stimulates protein 
kinase C activity in vascular smooth muscle cells, our 
results suggest an important role of protein kinase C 
activity in renal vasoconstriction induced by ANG II. 
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This conclusion is in good accordance with previous 
observations made on preparations of tracheal smooth 
muscles or on cultures from rat aorta (6, 30). 
Although calmodulin antagonists did not alter the 
constrictory effect of ANG II, our findings provide evi- 
dence that ANG II requires the entrance of calcium from 
the extracellular space to produce renal vasoconstriction. 
This estimation is based on the observations that the 
calcium antagonists cobalt, verapamil, and nifedipine 
attenuated or even blunted the constrictory effect of 
ANG II in the kidney. Because the effects of these agents 
were quickly reversible, it is likely that they exerted their 
effects by impeding transmembrane calcium entry rather 
than by unspecifically blocking receptors or enzymes. 
This conclusion fits with a number of studies emphasiz- 
ing the dependence of the renal vasoconstrictor action of 
ANG II on calcium entry (11, 20, 26, 29). 
A more interesting finding in our study was that the 1. 
vasoconstrictor effect of PMA was also inhibited by 
calcium antagonists. These results indicate that the con- 
strictory effect of PMA in the kidney is, like that of 
ANG II, highly dependent on calcium entry. A depend- 
ency of PMA-induced vasoconstriction on calcium entry 
is also in good accordance with recent results obtained 
by Schrier and co-workers (6) in cultures of rat aortic 
smooth muscle cells and with a concept developed by 
Rasmussen et al. (32-34) that a continuous transmem- 
brane Ca2+-cycling system is involved in the smooth 
muscle contractile effect of protein kinase C activators 
(27) 
One could speculate that protein kinase C activation 
enhances calcium influx into vascular smooth muscle 
cells and that this process is essentially involved in the 
constrictor action of ANG II. This view would be sup- 
ported by the findings that PMA enhances 45Ca uptake 
in cultures of rat renal mesangial ccl ls (31) and rat renal 
juxtaglomerular cells (24)) an effect that is inh ibited by 
the calcium channel blocker verapamil. Phorbol esters 
have also been shown to enhance calcium uptake by rat 
aortic smooth muscle cells (10, 13, 15, 21). 
Alternatively, it cannot be ruled out at present that 
renal vascular smooth muscle cells in situ have a high 
(basal) calcium permeability, being the prerequisite for 
rather than the result of protein kinase C action on 
contraction. If true, then, this argument should also hold 
for the action of ANG II. It would thus oppose the general 
opinion that ANG II actively enhances transmembrane 
calcium influx either by activating second messenger- 
operated calcium channels, as in renal juxtaglomerular 
cells (22), or by activation of voltage-gated calcium chan- 
nels, resulting from the depolarizing effect of ANG II on 
vascular smooth muscle cells (5). 
In either case, our findings suggest that the vasocon- 
strictor effect of ANG II in the kidney is essentially 
mediated by protein kinase C activation. Whether the 
supply with calcium, by enhancing calcium entry, is the 
dominant effect by which protein kinase C mediates the 
constrictory effect of ANG II remains to be clarified. 
Experimental findings on skinned vascular smooth mus- 
cle cells also indicate a direct effect of protein kinase C 
on the contraction process (9). Recently, it has been 
shown that activation of protein kinase C by tumor- 
promoting phorbol esters led to phosphorylation of my- 
osin light chains in vascular and tracheal smooth muscle 
preparations (18, 37). Thus it seems likely that protein 
kinase C activation could exert at least two effects that 
act in concert on contraction of smooth muscle cells in 
the kidney. 
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